Copyright
©The Author(s) 2016.
World J Cardiol. Feb 26, 2016; 8(2): 220-230
Published online Feb 26, 2016. doi: 10.4330/wjc.v8.i2.220
Published online Feb 26, 2016. doi: 10.4330/wjc.v8.i2.220
Entire cohort (n = 376) | Anemia (n = 239) | No anemia (n = 137) | P-value | |
Age, years ± SD | 81 ± 6.1 | 82 ± 6.2 | 81 ± 5.9 | 0.101 |
Male | 167 (44.4) | 112 (46.9) | 55 (40.1) | 0.207 |
Weight, kg ± SD | 74 ± 14.4 | 73 ± 14.2 | 75 ± 15.0 | 0.351 |
Height, cm ± SD | 168 ± 8.8 | 168 ± 8.7 | 168 ± 9.1 | 0.685 |
NYHA III and IV | 288 (76.6) | 187 (78.6) | 101 (73.7) | 0.284 |
CAD | 263 (69.9) | 170 (71.1) | 93 (67.9) | 0.209 |
Previous myocardial infarction | 39 (10.4) | 31 (13.0) | 8 (5.8) | 0.029 |
Previous percutaneous intervention | 168 (44.7) | 113 (47.3) | 55 (40.1) | 0.181 |
Previous CABG | 89 (23.7) | 55 (23.1) | 34 (24.8) | 0.708 |
Previous valve | 8 (2.1) | 5 (2.1) | 3 (2.2) | 0.954 |
Previous stroke | 34 (9.0) | 23 (9.6) | 11 (8.0) | 0.604 |
Diabetes mellitus | 93 (24.7) | 59 (24.7) | 34 (28.4) | 0.977 |
Hypertension | 355 (94.4) | 224 (93.7) | 131 (95.6) | 0.441 |
Peripheral vascular disease | 115 (30.6) | 75 (31.4) | 40 (29.2) | 0.658 |
Cerebroarterial vascular disease | 81 (21.5) | 56 (23.4) | 25 (18.2) | 0.239 |
COPD | 72 (19.1) | 46 (19.2) | 26 (19.0) | 0.949 |
Atrial fibrillation | 87 (23.1) | 52 (21.8) | 35 (25.5) | 0.414 |
Permanent pacemaker | 64 (17.0) | 43 (18.1) | 21 (15.3) | 0.497 |
Chronic kidney disease | 203 (54.0) | 144 (60.3) | 59 (43.1) | 0.001 |
Dialysis | 21 (5.6) | 19 (7.9) | 2 (1.5) | 0.009 |
Aortic valve area, cm²± SD | 0.73 ± 0.2 | 0.71 ± 0.19 | 0.75 ± 0.22 | 0.094 |
Mitral regurgitation ≥ grade II | 114 (30.3) | 73 (32.2) | 41 (31.5) | 0.904 |
LVEF < 30% | 20 (5.3) | 16 (6.7) | 4 (2.9) | 0.253 |
LVEF 30%-44% | 68 (18.1) | 47 (19.7) | 21 (15.3) | 0.292 |
LVEF 45%-55% | 49 (13.0) | 29 (12.1) | 20 (14.6) | 0.493 |
LVEF > 55% | 239 (63.6) | 147 (61.5) | 92 (67.2) | 0.273 |
Logistic EuroSCORE, % ± SD | 19.7 ± 12.9 | 20.5 ± 13.1 | 18.4 ± 12.5 | 0.133 |
Baseline hemoglobin, g/dL ± SD | 11.9 ± 1.7 | 11.0 ± 1.1 | 13.6 ± 1.1 | < 0.001 |
Baseline RDW, % ± SD | 15.0 ± 1.8 | 15.4 ± 1.8 | 14.4 ± 1.6 | < 0.001 |
Baseline serum creatinine, mg/dL ± SD | 1.3 ± 1.1 | 1.5 ± 1.2 | 1.0 ± 0.5 | < 0.001 |
Baseline GFR, mL/min ± SD | 58.7 ± 23.7 | 54.5 ± 23.6 | 65.9 ± 22.2 | < 0.001 |
Baseline CRP, mg/dL ± SD | 1.2 ± 1.8 | 1.4 ± 2.0 | 0.8 ± 1.1 | < 0.001 |
TF access | 270 (71.8) | 172 (72.0) | 98 (71.5) | 0.742 |
TA access | 105 (27.9) | 66 (27.6) | 39 (28.5) | 0.862 |
TS access | 1 (0.3) | 1 (0.4) | 0 (0.0) | 0.637 |
- Citation: Hellhammer K, Zeus T, Verde PE, Veulemanns V, Kahlstadt L, Wolff G, Erkens R, Westenfeld R, Navarese EP, Merx MW, Rassaf T, Kelm M. Red cell distribution width in anemic patients undergoing transcatheter aortic valve implantation. World J Cardiol 2016; 8(2): 220-230
- URL: https://www.wjgnet.com/1949-8462/full/v8/i2/220.htm
- DOI: https://dx.doi.org/10.4330/wjc.v8.i2.220